17:52:10 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.

Kalender

2023-03-02 Kvartalsrapport 2023-Q2
2022-11-17 Årsstämma 2023
2022-10-25 Ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 Bokslutskommuniké 2022
2022-02-24 Kvartalsrapport 2022-Q2
2021-10-29 Ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 Årsstämma 2022
2021-09-15 Bokslutskommuniké 2021
2022-06-29 15:45:00

Company release, 29 June 2022 at 4:45 p.m. (EEST)

The Extraordinary General Meeting of Nightingale Health Plc was held today on 29 June 2022 in Helsinki. To limit the spread of the Covid 19 -pandemic, shareholders or their proxy representatives could not participate in the meeting at the meeting venue. The General Meeting supported the Board of Directors' proposal to the General Meeting, set out in the notice to the General Meeting sent on 8 June 2022, to add an addition to the Articles of Association concerning remote participation in the General Meeting as an alternative way to attend the meeting or in lieu of convening to a physical meeting.

The General Meeting resolved, subject to the entering into force of the governmental proposal 47/2022 relating to the matter, to amend Section 12 of the Articles of Association of Nightingale Health Plc by adding the option to the Board of Directors to decide on organising a General Meeting so that the shareholders may use their decision-making rights through telecommunication and technical means, or so that General Meeting is arranged without a meeting venue and the shareholders exercise their decision-making rights fully through telecommunications and technical means.

The minutes of the General Meeting, including an English translation, will be available on the website of the company at the latest on 13 July 2022.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified Adviser:
Oaklins Merasco Ltd. tel. +358 9 6129 670

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.